

**IN THE CLAIMS:**

✓✓  
Please **cancel** claims 1-7 without prejudice or disclaimer.

Please **amend** the claims as follows:

8. (Amended) A modified recombinant allergen wherein at least one of the T-cell reactive regions 16-42, 135-149 and 180-206 of the Ph1 p 5b polypeptide, consisting of a total of 265 amino acids, is not altered.

9. (Amended) A modified recombinant allergen according to claim 8, selected from:

E7

PM1	(N <sup>32</sup> → D, D <sup>49</sup> → L, K <sup>50</sup> → A)	(SEQ ID NO. 88)
PM2	(D <sup>49</sup> → L, K <sup>50</sup> → A)	(SEQ ID NO. 89)
PM3	(A <sup>13</sup> → C)	(SEQ ID NO. 90)
DM1	(Δ K <sup>50</sup> → P <sup>Δ132</sup> , D <sup>49</sup> → L)	(SEQ ID NO. 91)
DM2	(Δ F <sup>51</sup> - G <sup>178</sup> , D <sup>49</sup> - L, K <sup>50</sup> - A)	(SEQ ID NO. 92)
DM2*	(Δ F <sup>51</sup> - G <sup>178</sup> , 179 - 217 altered sequence) or	
DM3	(Δ A <sup>154</sup> - T <sup>177</sup> , A <sup>220</sup> → T)	(SEQ ID NO. 93).

E8

11. (Amended) A pharmaceutical preparation for treating an IgE-mediated allergy comprising at least one modified recombinant allergen according to claim 8 and a pharmaceutically acceptable carrier.

Please **ADD** the following new claims:

--15. The pharmaceutical preparation according to claim 11 comprising a physiologically compatible salt or solvate of said recombinant modified allergen.

16. The pharmaceutical preparation according to claim 11 comprising an additional active compound.

17. A modified recombinant allergen having a region which corresponds to at least one of the T-cell reactive regions 16-42, 135-149, and 180-206 of the Phl p 5b polypeptide, consisting of a total of 265 amino acids, wherein at least one of said regions is not altered.

E9 18. A modified recombinant allergen of claim 17, wherein a combination of said regions is present and is not altered.

19. A modified recombinant allergen according to claim 17, selected from:

PM1	(N <sup>32</sup> → D, D <sup>49</sup> → L, K <sup>50</sup> → A)	(SEQ ID NO. 88)
PM2	(D <sup>49</sup> → L, K <sup>50</sup> → A)	(SEQ ID NO. 89)
DM1	(Δ K <sup>50</sup> → P <sup>Δ132</sup> , D <sup>49</sup> → L)	(SEQ ID NO. 91) or
DM3	(Δ A <sup>154</sup> - T <sup>177</sup> , A <sup>220</sup> → T)	(SEQ ID NO. 93).

20. The modified recombinant allergen according to claim 8, wherein "modified" refers to a wild type polypeptide that is altered by a substitution.

21. The modified recombinant allergen according to claim 17, wherein "modified" refers to a wild type polypeptide that is altered by a deletion.

22. An allergen of claim 8, wherein a combination of said regions is present and is not altered.

E9  
23. A method for manufacturing an allergen showing a reduced or eliminated reactivity with IgE antibodies and a retained reactivity with T-lymphocytes, comprising:

- determining the amino acid sequence of a natural protein allergen,
- creating a series of overlapping oligopeptides, derived from the sequence of the allergen by methods known in the art,
- obtaining T-cell clones from patients allergic to said allergen,
- screening said oligopeptides for their ability to react with and stimulate said T-cell clones, and
- creating mutants of said allergen while leaving unaltered one or more of the T-cell reactive sequence regions. --